A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn’t catching a break this year. Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed…
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in the U.S. Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company’s patents and…
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone. Top executives from drugmakers big and small told CNBC that the next phase…
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity…
Read More “First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. ” »
President Donald Trump‘s move Thursday to sign an executive order easing federal restrictions on marijuana — and clearing the way for a Medicare pilot program covering CBD — caps a coordinated, yearlong push by the cannabis industry that combined traditional lobbying, sizable political donations, data-driven messaging and direct outreach to the president’s inner circle, industry…
Read More “Inside the dealmaking that pushed Trump to reclassify pot, expand access” »
Health and Human Services Secretary Robert F. Kennedy Jr.’s hand-picked vaccine committee on Thursday deferred crucial votes on hepatitis B vaccines for babies until Friday, saying it will give members more time to review proposed language on the measure. One panel member, Dr. Cody Meissner, a professor of pediatrics at the Dartmouth Geisel School of…
Read More “RFK Jr.’s vaccine panel defers vote on hepatitis B shot for babies until Friday” »
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to…
Read More “Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month” »
New Delhi: India’s coffee exports have continued their strong upward trajectory, maintaining their billion-dollar streak for the fourth consecutive financial year, according to the Department of Commerce under the Ministry of Commerce and Industry. During the financial year 2024-25, India’s coffee exports reached USD 1.80 billion, marking a 40.2 per cent growth over the USD…
Read More “Indias Coffee Exports Hit USD 1.8 billion In FY25, Continues Four-Year Growth Streak” »
Oils containing CBD (Cannabidiol). Geoffroy Van Der Hasselt | AFP | Getty Images Cannabis stocks could be poised for a rally after years of stagnation, fueled by investor optimism over the possibility for new federal rules for hemp-derived products and signals that President Donald Trump could take a more permissive stance on marijuana. Publicly traded…
U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca announced Friday they have reached an agreement for the U.K.-based pharmaceutical giant to cut drug…
Read More “Trump reaches deal with AstraZeneca to lower U.S. drug prices” »
 "Indias Coffee Exports Hit USD 1.8 billion In FY25, Continues Four-Year Growth Streak")
